SeraCare’s Post

🧪 Researchers designed a phase 2 randomized trial to compare drug-eluting beads transarterial chemoembolization with #irinotecan and mitomycin C versus DEB-TACE with #doxorubicin for patients with intermediate-stage #hepatocellular carcinoma. 👉 Learn more about the results presented at #ESMO24:

💡“𝗙𝗿𝗼𝗺 𝗘𝘀𝗰𝗮𝗹𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗪𝗲𝗮𝗻𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀—𝗛𝗼𝘄 𝘁𝗼 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲 𝘁𝗵𝗲 𝗘𝗖𝗠𝗘𝗟𝗟𝗔 𝗖𝗼𝗻𝗰𝗲𝗽𝘁.” Benedikt Schrage, MD, discusses his paper, “From Escalation to Weaning Strategies—How to Integrate the ECMELLA Concept.” He explains the rationale behind the ECMELLA approach, which combines mechanical circulatory support (MCS) with an Impella® device with veno-arterial extracorporeal membrane oxygenation (VA ECMO); he describes why it is relevant in the treatment of patients with cardiogenic shock. 𝗧𝘄𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀 𝗶𝗻 𝘄𝗵𝗶𝗰𝗵 𝗲𝘀𝗰𝗮𝗹𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗘𝗖𝗠𝗘𝗟𝗟𝗔 𝘀𝗵𝗼𝘂𝗹𝗱 𝗯𝗲 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱, 𝗮𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻, 𝗮𝗿𝗲: 1️⃣ Patient has deteriorating cardiogenic shock (SCAI stage D or E) despite treatment with a mAFP and VA ECMO is added to augment cardiac output and increase tissue perfusion and oxygenation 2️⃣ Patient in severe cardiogenic shock (SCAI stage D or E) requires immediate VA ECMO for tissue perfusion/oxygenation and mAFP to unload the LV and facilitate myocardial recovery

🚀 Advancing personalized tissue therapies: VERIGRAFT P-TEV clinical trial update 🚀 We are excited to share progress from our ongoing Phase I/II clinical trial in Europe! Eleven of the planned fifteen patients have now been treated with our Personalized Tissue-Engineered Vein (P-TEV) product, and four of these patients have completed the twelve-month follow-up period. Our trial aims to evaluate P-TEV’s potential to cure chronic venous insufficiency, a condition caused by faulty valves that fail to prevent venous blood backflow. Primary endpoints focus on safety, assessing risks such as infection, mechanical failure, and thrombosis. Secondary endpoints will measure treatment efficacy. “So far, the results are exceeding expectations, confirming safety and showing significant promise for our innovative approach,” said Petter Björquist, CEO of VERIGRAFT. “Our commitment to advancing regenerative medicine and providing personalized treatments that enhance recovery and improve quality of life is yielding encouraging outcomes." 🔗 Click the link in the comments section below to learn more about VERIGRAFT’s innovative tissue therapy technology 👇   #RegenerativeMedicine #ClinicalTrials #HealthInnovation #PersonalizedTherapies #PrecisionMedicine #ChronicVenousInsufficiency #PTEV #Gothenburg #Sweden #VERIGRAFT SwedenBIO CCRM Nordic Business Region Göteborg AB ATMP Sweden SwedenBIO Business Sweden

It will be a great webinar on CAR T cells.

Unleash the potential of liquid biopsy with Caris Assure, an innovative multi-cancer assay that provides deep molecular insights from a simple blood sample. Explore how this powerful liquid #biopsy assay can revolutionize patient care. Learn more: https://ow.ly/6XMo50SBG4z #precisionmedicine

#WorldCancerDay is an international day marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. Uson is honored to assist several #medicaldevice manufactures with the development of #leaktesting specifications and equipment for a variety of devices used to treat cancer. Our part in the battle against cancer is small, but our commitment to helping manufactures ensure the #safety and #quality of their medical device products used to fight the disease is HUGE. #worldcancerday #engineering #leaktesting #leakdetection #manufacturing #quality #medical #medicaldevice #medicalequipment #medicalautomation

Employee health benefits that actually benefit PEOPLE. Take a look at our insightful webinar discussing HealthEZ's Medical Infusion Program (MICO) and learn how we put the patient at the center of everything that we do while continuing to control and predict cost for employee benefits. #HealthEZ #MICO #MedicalInfusions #CostContainment

Today, September 7, we acknowledge World Duchenne Muscular Dystrophy Awareness Day and extend our deepest gratitude to the Duchenne community and C-Path’s Duchenne Regulatory Science Consortium members for their tireless dedication to advancing treatments for DMD. To combat the many challenges posed by this disease, D-RSC has created an integrated database of patient-level clinical data from DMD studies, and several drug development tools available to the Duchenne community with permissions. Established by C-Path and Parent Project Muscular Dystrophy, D-RSC, in partnership with CDISC, has also developed standard terminology and authored the Duchenne Muscular Dystrophy Therapeutic Area User Guide and the Cardiac Imaging Supplement currently out for public review until September 30.   We are proud to continue this work and are grateful for the community’s ongoing collaboration. For more information, visit c-path.org/programs/d-rsc. To view the Cardiac Imaging Supplement, visit: https://lnkd.in/g8ujGTsV   Ramona Belfiore-Oshan, Pat Furlong   #CPath #DMDawareness #WDAD2024 #musculardystrophy #raredisease #drugdevelopment #datasharing #globalhealth #collaboration #CDISC

Please join us on Monday, 15 - April, for webinar on how CAR T assay data can be utilized to monitor CAR T cells, patient response to treatment and patient safety

In a phase II trial led by Elias Jabbour, MD, of MD Anderson Cancer Center, #dasatinib plus #venetoclax was effective and safe for pts with chronic phase #chronicmyeloidleukemia #CML, #Heme https://lnkd.in/eKPiSkq3